Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma

This study has been completed.
Sponsor:
Information provided by:
Celgene Corporation
ClinicalTrials.gov Identifier:
NCT00065351
First received: July 21, 2003
Last updated: September 22, 2009
Last verified: September 2009
  Purpose

For each subject the study will consist of two phases: a treatment phase and a follow-up phase. Screening procedures will take place within 28 days of baseline.

Treatment Phase: Subjects who qualify for enrollment into the study will receive single-agent CC-5013 in 28-day cycles. Study visits will occur every 4 weeks and hematologic and myeloma paraprotein laboratory assessments will occur every 2 weeks for the first 6 cycles and every 4 weeks thereafter.

Follow-Up Phase: All subjects who discontinue the treatment phase for any reason will continue to be followed for survival and post-treatment phase anti-myeloma treatment.


Condition Intervention Phase
Multiple Myeloma
Drug: CC-5013
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multicenter, Open-label Study to Determine the Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma

Resource links provided by NLM:


Further study details as provided by Celgene Corporation:

Primary Outcome Measures:
  • Myeloma response [ Time Frame: randomization to progression ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Time to tumor progression [ Time Frame: randomization to progression ] [ Designated as safety issue: No ]
  • Duration of response [ Time Frame: randomization to progression ] [ Designated as safety issue: No ]
  • Survival (1-year and overall survival) [ Time Frame: 1 year and ongoing ] [ Designated as safety issue: No ]
  • Time to first skeletal-related event (SRE) (clinical need for radiation or surgery to bone) [ Time Frame: randomization to progression ] [ Designated as safety issue: Yes ]
  • Safety (type, frequency, severity, and relationship of adverse events to study drug) [ Time Frame: ongoing ] [ Designated as safety issue: Yes ]

Enrollment: 222
Study Start Date: July 2003
Study Completion Date: March 2007
Primary Completion Date: October 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
CC-5013 - oral - 30mg daily on days 1-21 every 28 days
Drug: CC-5013
CC-5013 - oral - 30mg daily on days 1-21 every 28 days

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Understand and voluntarily sign an informed consent form.
  • Age greater than or equal to 18 years at the time of signing the informed consent form.
  • Must have a diagnosis of multiple myeloma and have relapsed and refractory disease. Such subjects have relapsed after having had at least a partial myeloma paraprotein response (greater or equal to 50% reduction of myeloma paraprotein) to prior therapy and then continued to develop disease progression despite salvage anti-myeloma therapy. Subjects must have documented evidence of disease progression during therapy with the last prior anti-myeloma treatment regimen (must have received at least 2 cycles) prior to study enrollment.Subjects may have been previously treated with thalidomide and/or radiation therapy.
  • Measurable levels of myeloma paraprotein in serum (greater or equal to 0.5 g/dL) or urine (greater or equal to 0.2 g excreted in a 24-hour collection sample).
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2 (see Appendix II).
  • Able to adhere to the study visit schedule and other protocol requirements
  • Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test within 7 days of starting study drug.

Exclusion Criteria:

  • Sexually active WCBP must agree to use adequate contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) while on study drug.
  • WCBP must agree to have pregnancy tests every 4 weeks while on study drug (every 14 days for women with irregular cycles) and 4 weeks after the last dose of study drug.
  • Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
  • Pregnant or lactating females.
  • Any of the following laboratory abnormalities:

A) Absolute neutrophil count (ANC) <1,000 cells/mm^3 (1.0 x 10^9/L) B) Platelet count <75,000/mm^3 (75 x 10^9/L) C) Serum creatinine >2.5 mg/dL (221 umol/L) D) Serum SGOT/AST or SGPT/ALT >3.0 x upper limit of normal (ULN) E) Serum total bilirubin >2.0 mg/dL (34 umol/L)

  • Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
  • Prior history of malignancies other than multiple myeloma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the subject has been free of the disease for greater than or equal to 3 years.
  • Prior greater than or equal to grade 3 allergic reaction/hypersensitivity to thalidomide.
  • Prior greater than or equal to grade 3 rash or any desquamating (blistering) rash while taking thalidomide.
  • Prior use of CC-5013.
  • Use of any standard/experimental anti-myeloma drug therapy within 28 days of the initiation of study drug therapy or use of any experimental non-drug therapy within 56 days of the initiation of study drug therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00065351

  Hide Study Locations
Locations
United States, Arizona
Palo Verde Hematology Oncology
Glendale, Arizona, United States, 85304
Mayo Clinic
Scottsdale, Arizona, United States, 85259
United States, California
Alta Bates Comprehensive Cancer Center
Berkeley, California, United States, 94704
Providence St. Joseph Medical Center/Cancer Center
Burbank, California, United States, 91505
Wilshire Oncology Medical Group, Inc.
La Verne, California, United States, 91750
Institute for Myeloma and Bone
Los Angeles, California, United States, 90067
Cancer Care Associates
Redondo Beach, California, United States, 90277
United States, Florida
Mayo Clinic
Jacksonville, Florida, United States, 32224
United States, Georgia
Northwest Georgia Oncology Centers
Marietta, Georgia, United States, 30060
Atlanta Cancer Care-Roswell
Roswell, Georgia, United States, 30076
United States, Illinois
Northwestern University Med Ctr
Chicago, Illinois, United States, 60611-2927
Midwest Cancer Research Group
Skokie, Illinois, United States, 60077
United States, Maryland
University of Maryland Medical Center
Baltimore, Maryland, United States, 21201-1595
Center for Cancer and Blood Disorders
Bethesda, Maryland, United States, 20717
United States, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
University of Massachusetts
Worcester, Massachusetts, United States, 01655
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55902
United States, Nevada
Nevada Cancer Center
Las Vegas, Nevada, United States, 89109
United States, New York
SUNY Health Science Center at Brooklyn
Brooklyn, New York, United States, 11203
St. Vincent's Comprehensive Cancer Center
New York, New York, United States, 10011
United States, North Carolina
Carolina Hematology-Oncology Associates
Charlotte, North Carolina, United States, 28203
United States, Ohio
Cleveland Clinic Myeloma Program Hematology & Medical Oncology /R35
Cleveland, Ohio, United States, 44195
United States, Pennsylvania
Western Pennsylvania Cancer Institute
Pittsburgh, Pennsylvania, United States, 15224
United States, Washington
Swedish Cancer Institute
Seattle, Washington, United States, 98104
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States, 98109-1024
Sponsors and Collaborators
Celgene Corporation
Investigators
Study Director: Robert Knight, MD Celgene Corporation
  More Information

No publications provided by Celgene Corporation

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Robert Knight, MD - VP Hematology, Celgene Corporation
ClinicalTrials.gov Identifier: NCT00065351     History of Changes
Other Study ID Numbers: CC-5013-MM-014
Study First Received: July 21, 2003
Last Updated: September 22, 2009
Health Authority: United States: Food and Drug Administration

Keywords provided by Celgene Corporation:
Multiple Myeloma
CC-5013
Revlimid
MM
CC5013
relapsed and refractory multiple myeloma

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Lenalidomide
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 24, 2014